Skip to content
Screener

Organon OGN Follistim AQ — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%
Flanigan's Enterprises logo
BDLOther Revenues — Revenue
$88K+27.5%
American Electric Power logo
AEPCommercial Revenues — Revenue
$1.21B+15.4%
Equinix, Inc. logo
EQIXRecurring revenues — Revenue
$2.38B+10.9%
GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532
($ in millions)Three Months Ended March 31, 2025 / U.S.2025 / Int’lTotalU.S.Int’lTotal
Women’s Health
Nexplanon/Implanon NXT$127$74$201$176$72$248
Follistim AQ213961353469
NuvaRing6182461622
Ganirelix Acetate Injection2242652327
Marvelon/Mercilon—2626—3939
Jada5—515—15
Other Women’s Health (1)173046152743

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's follistim AQ — revenue?
Organon (OGN) reported follistim AQ — revenue of $61M in Q1 2026.
How has Organon's follistim AQ — revenue changed year-over-year?
Organon's follistim AQ — revenue decreased by 11.6% year-over-year, from $69M to $61M.
What is the long-term trend for Organon's follistim AQ — revenue?
Over 4 years (2021 to 2025), Organon's follistim AQ — revenue has grown at a 2.8% compound annual growth rate (CAGR), from $237M to $265M.
What does follistim AQ — revenue mean?
This metric represents the total gross sales generated from the Follistim AQ product line, a key therapeutic solution within the company's women's health portfolio. It reflects the market demand and commercial performance of this specific fertility treatment across global markets. Tracking this revenue stream provides insight into the company's ability to maintain its competitive position in the specialized reproductive health sector.

Ask your AI about Organon's follistim aq — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude